FDA Adverse Event Malfunction Summary report: N

GALILEO

MDR report key: 1163324 · Received September 19, 2008

Report

Report Number
1034569-2008-00445
Event Type
Malfunction
Date Received
September 19, 2008
Date of Event
September 21, 2008
Report Date
September 10, 2008
Manufacturer
IMMUCOR, INC.
Product Code
KSZ
PMA / PMN Number
BK040013
Product Problem
Yes
Report Source
Manufacturer report
Reporter Location
KY, US
Reporter Occupation
MEDICAL TECHNOLOGIST

Narratives

Additional Manufacturer Narrative · 1

REACTIVITY OF THE E, C AND JKA ANTIGENS WERE CONFIRMED ON RETENTION CRRS(I AND II), LOT X253, CRRID, LOTS ID104 AND DP029. CUSTOMER RETURNED SAMPLE FOR INVESTIGATION TESTING. TESTING IS ONGOING. THE CUSTOMER'S RETURNED SAMPLES WERE TESTED WITH RETENTION CRRS(I AND II), LOT X253 ON AN IN-HOUSE GALILEO INSTRUMENT. MODERATE TO STRONG REACTIVITY WAS OBSERVED WITH CELL II {(C-E+E-C+;JK(A+B-)}. THE SAMPLE WAS TESTED WITH RETENTION CRRID, LOT ID104 ON AN IN-HOUSE GALILEO. IDENTICAL REACTIVITY BETWEEN CUSTOMER'S TESTING AND OUR TESTING WAS OBSERVED WITH CELL 1 TO CELL 8, 10 AND 14. OUR IN-HOUSE GALILEO INSTRUMENT GAVE 1+ TO 2+ REACTIVITY IN CELL # 11, 12 AND 13 (DID NOT GIVE EQUIVOCAL (?) AS CUSTOMER OBSERVED). IN CELL 9, OUR GALILEO GAVE NEGATIVE REACTIVITY (CUSTOMER GOT (?) EQUIVOCAL REACTIVITY). WE CANNOT RULE OUT OTHER CLINICALLY SIGNIFICANT ALLOANTIBODIES. THE CUSTOMER'S SAMPLE WAS TESTED IN HEMAGGLUTINATION TESTS WITH SELECTED CELLS FROM PANOCELL-20, LOT 28841, USING IMMUADD AS THE POTENTIATOR. ONLY VERY WEAK MICROSCOPIC REACTIVITY WAS OBSERVED.

Description of Event or Problem · 1

CUSTOMER INDICATED THAT AN ANTIBODY PANEL COMPLETED ON GALILEO SHOWED WEAK TO NO REACTIVITY ON A PATIENT WHICH HAD AN ANTI-C. THE CUSTOMER STATED THAT BASED ON THE REACTIVITY OF THE ANTIBODY ID PANEL, ANTI-C WAS RULED OUT. THE CUSTOMER INDICATED THAT THE UNEXPECTED REACTIONS DID NOT RESULT IN AN ADVERSE PATIENT EVENT.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1 GALILEO AUTOMATED BLOOD BANK ANALYZER KSZ IMMUCOR, INC.

Patients

Seq Age Sex Outcome Treatment
1 84 YR